GLP-1 and Iron Deficiency: Ferritin, Anemia, Hair Loss Connection

Iron deficiency is the most common nutritional deficiency in the world and the single most common cause of anemia (Camaschella 2015 NEJM^[1], Pasricha 2021 Lancet^[2]). In the United States it affects roughly 10% of premenopausal women and about 3% of men. On a GLP-1, three of the four pathways to iron deficiency are simultaneously amplified: dietary intake drops as appetite drops, the absorption window shifts as gastric emptying slows, and red-meat aversion (a documented GLP-1 side effect) cuts heme iron specifically. The result is the same picture clinicians already recognize from bariatric surgery: ferritin trending down within the first six to twelve months, hair shedding when ferritin crosses below roughly 70 ng/mL (Trost 2006^[3], Olsen 2010^[4]), and a small but real fraction of patients who require IV iron because oral iron is intolerable on top of GLP-1 nausea. This article walks through the mechanism, the workup, and the practical repletion protocol.

The honest summary

• Iron deficiency is the most common nutritional deficiency. Camaschella 2015^[1] and Pasricha 2021^[2] are the canonical clinical reviews. Roughly 10% of US premenopausal women and 3% of men are deficient; menstruating women, vegetarians, and post-bariatric patients are the highest-risk groups.
• Ferritin below ~70 ng/mL is the hair-loss threshold. Trost 2006^[3] reviewed the dermatology literature and identified ferritin under roughly 70 ng/mL as the level at which telogen effluvium becomes clinically meaningful; Olsen 2010^[4] quantified the relationship in female pattern hair loss and chronic telogen effluvium specifically.
• GLP-1 mechanism: intake, not malabsorption. Unlike Roux-en-Y gastric bypass, GLP-1 medications do not bypass the duodenum where heme and non-heme iron are absorbed, and gastric acid secretion is preserved. The dominant pathway is reduced food intake amplified by meat aversion and slowed gastric emptying.
• Alternate-day dosing absorbs better. Stoffel 2017 Lancet Haematology^[6] and von Siebenthal 2023^[7] both showed that alternate-day oral iron produces higher cumulative fractional absorption than consecutive-day dosing, because daily dosing transiently raises hepcidin and blunts the next day’s uptake.
• IV iron is indicated for oral intolerance. Schijns 2020^[9] (RYGB RCT) and Auerbach 2021^[10] (ferric derisomaltose) document the modern IV iron formulations and their safety profile in patients who cannot tolerate oral iron — a population that overlaps heavily with GLP-1 users.

Mechanism: why GLP-1 patients lose iron

Iron homeostasis depends on intake, absorption, and loss. Healthy non-menstruating adults lose roughly 1 mg of iron per day through desquamation; menstruating women lose an additional 0.5–1.5 mg per day averaged across the cycle. Replacement comes entirely from the gut, and absorption is tightly regulated by hepcidin, the master hormone produced in the liver.

Dietary iron exists in two forms. Heme iron (from hemoglobin and myoglobin in red meat, poultry, and fish) is absorbed at 15–35% efficiency and is largely independent of gastric acid. Non-heme iron (from plants, fortified grains, and supplements) is absorbed at 2–20% efficiency and requires gastric acid to reduce ferric (Fe3+) to the absorbable ferrous (Fe2+) form. Vitamin C in the same meal can double non-heme absorption; calcium, polyphenols in coffee and tea, and phytates in whole grains cut it.

GLP-1 receptor agonists do not directly impair iron transport across the duodenal enterocyte. The clinically relevant pathways are upstream:

• Reduced total intake. A 30–40% appetite reduction drops total food intake and, with it, total dietary iron.
• Meat aversion. Red meat is the highest- density source of heme iron and is one of the foods most commonly reported as suddenly unpalatable on a GLP-1. Patients shifting toward chicken, fish, dairy, and plant protein lose disproportionate amounts of bioavailable heme iron.
• Slowed gastric emptying. Iron supplements taken close to a meal may pass through the duodenum during the slow-emptying window when food is still present, shifting the absorption profile.
• Preserved gastric acid. Unlike bariatric sleeve gastrectomy, GLP-1 therapy preserves parietal cell acid production. This is the reason GLP-1-associated iron deficiency is generally less severe than post-RYGB deficiency (Aills 2008 ASMBS guidelines^[8]).

The hair-loss connection: ferritin under ~70 ng/mL

Trost 2006^[3] reviewed the dermatology literature on iron and hair and identified ferritin below roughly 70 ng/mL as the threshold below which telogen effluvium (diffuse shedding) becomes clinically common. Olsen 2010^[4] measured serum ferritin in women with female pattern hair loss, chronic telogen effluvium, and matched controls and reported lower mean ferritin in both shedding groups. Goldberg 2010^[5] reviewed the broader nutrition-and-hair literature and reached the same conclusion: optimal hair growth requires ferritin in roughly the 70–100 ng/mL range, with shedding increasing below that band.

Two practical implications follow. First, the lab reference range for “normal” ferritin (usually 15–200 ng/mL) is anchored to anemia prevention, not hair preservation. A patient with ferritin of 25 ng/mL is not anemic but is well below the hair-growth threshold. Second, treating shedding on a GLP-1 with topical minoxidil without checking ferritin is a frequent miss. The hair-loss workup should include ferritin every time.

The workup: which labs to order

The minimum workup for suspected iron deficiency on a GLP-1 is a complete blood count plus iron studies. The full panel:

• CBC: hemoglobin, hematocrit, MCV (microcytic anemia: MCV under 80 fL), red cell distribution width.
• Iron studies: serum ferritin (the storage marker), transferrin saturation (TSAT), serum iron, total iron-binding capacity (TIBC).
• Soluble transferrin receptor (sTfR): if inflammation is suspected, because ferritin is an acute-phase reactant and can be falsely elevated. sTfR rises with true iron deficiency and is unaffected by inflammation.
• Reticulocyte count: low in iron deficiency anemia.
• C-reactive protein: to interpret ferritin against inflammation.

Interpretation thresholds from Camaschella 2015^[1] and Pasricha 2021^[2]:

• Ferritin < 15 ng/mL: severe iron deficiency, almost always with anemia.
• Ferritin < 30 ng/mL: iron deficient regardless of hemoglobin.
• Ferritin < 70 ng/mL: the hair-loss threshold (Trost 2006^[3]).
• Ferritin 70–100 ng/mL: generally considered optimal for hair growth and active women.
• TSAT < 20%: functionally iron deficient even with normal ferritin.

The differential for fatigue and hair shedding on a GLP-1 should also screen for vitamin B12, folate, vitamin D, and thyroid disease. Persistent deficiency despite repletion warrants a celiac screen (tissue transglutaminase IgA) and, for older patients, age-appropriate colorectal cancer screening to rule out occult GI bleeding.

Magnitude: ferritin change at 12 months

Oral iron: which form, how much, when

Three oral iron preparations are widely available in the United States:

• Ferrous sulfate 325 mg (65 mg elemental iron). The cheapest and most studied form. Constipation and GI upset are dose-related.
• Ferrous gluconate 240 mg (28 mg elemental iron). Lower elemental dose per tablet, generally better tolerated, often used as the first step-down from ferrous sulfate.
• Polysaccharide-iron complex (Niferex, 150 mg elemental iron per capsule). Marketed as better tolerated; the absorption advantage over ferrous sulfate is debated in the literature.

The most important dosing update in the last decade is alternate-day dosing. Stoffel 2017^[6] in Lancet Haematology randomized iron-depleted women to 60 mg or 120 mg elemental iron given either daily or on alternate days. Cumulative fractional absorption was higher on the alternate-day arms because daily dosing transiently elevated serum hepcidin and suppressed the next morning’s absorption. von Siebenthal 2023^[7] extended the finding in a placebo-controlled RCT and confirmed the same absorption advantage. The practical protocol that emerges: 65 mg elemental iron (one ferrous sulfate tablet) every other morning, on an empty stomach, with 100 mg of vitamin C and not within two hours of dairy, calcium supplements, coffee, or tea.

Two GLP-1-specific cautions apply. First, oral iron is constipating, and GLP-1 medications already slow GI transit; the combination can be miserable. Starting at the alternate-day cadence rather than daily often resolves it. Second, taking iron immediately after a semaglutide or tirzepatide injection (during the peak nausea window) is a common reason for non-adherence; midweek between injections is the better window.

When IV iron is the right answer

IV iron is indicated for severe deficiency, oral intolerance, or failure to respond to a six-month oral trial. Modern formulations are far safer than the older iron dextran preparations and can deliver a full repletion dose in one or two visits:

• Iron sucrose (Venofer): typically 200 mg per infusion, total course 1,000 mg.
• Ferric gluconate (Ferrlecit): 125 mg per dose, eight-dose course.
• Ferric carboxymaltose (Injectafer): up to 750 mg per dose, total course 1,500 mg in two visits.
• Ferric derisomaltose (Monoferric): up to 1,000 mg in a single infusion. Auerbach 2021^[10] documented the safety profile.
• Ferumoxytol (Feraheme): 510 mg per dose, two-dose course.

Schijns 2020^[9] randomized post-RYGB patients with iron deficiency to oral or IV iron and reported higher hemoglobin response and faster ferritin recovery in the IV arm. The same logic applies to GLP-1 patients who cannot tolerate oral iron because of nausea or constipation: a single 1,000 mg infusion can reset stores in one visit and sidestep the daily adherence problem entirely. Cost is the main barrier — oral iron is $5–30 per month, whereas IV iron runs $1,500–5,000 per dose depending on formulation and site of care, and prior authorization is usually required.

The practical protocol

1. Baseline labs for every GLP-1 patient. CBC plus ferritin, TSAT, and serum iron before starting therapy. High-risk groups (menstruating women, vegetarians, prior bariatric surgery, known iron deficiency) also get sTfR and CRP.
2. Repeat at 6 and 12 months. CBC plus ferritin and TSAT at each interval. Order earlier if shedding, fatigue, palpitations, restless legs, or pica develop.
3. Supplement if ferritin < 70 ng/mL. Start ferrous sulfate 325 mg (65 mg elemental iron) every other morning, on an empty stomach, with 100 mg vitamin C. Avoid dairy, calcium, coffee, and tea within two hours.
4. Recheck at 8–12 weeks. Expected ferritin rise on the alternate-day Stoffel protocol is 15–30 ng/mL per 12 weeks. Hemoglobin responds first (a 1 g/dL rise at 4 weeks is the textbook target); stores take longer.
5. Escalate to IV iron if oral iron is intolerable, ferritin remains under 30 ng/mL at 6 months despite adherence, or anemia is severe (hemoglobin under 10 g/dL). Ferric carboxymaltose or ferric derisomaltose can complete a 1,000–1,500 mg course in one or two visits.
6. Re-screen the differential if repletion fails. B12, folate, thyroid, celiac (tissue transglutaminase IgA), and age-appropriate colorectal screening.

Special populations

Menstruating women account for the majority of GLP-1-associated iron deficiency. Heavy menstrual bleeding (more than 80 mL per cycle) is itself an indication for evaluation and iron supplementation regardless of GLP-1 status. Vegetarians and vegans on a GLP-1 are at amplified risk because the protein sources they rely on (legumes, tofu, dairy) carry little heme iron; targeted supplementation should start at GLP-1 initiation, not after deficiency appears. Pregnancy is a contraindication to GLP-1 therapy, but baseline iron stores at the time of conception determine first-trimester risk; women planning pregnancy should be repleted before discontinuation. Prior bariatric surgery patients on a GLP-1 carry double risk and warrant quarterly labs in the first year.

Related research and tools

• GLP-1 hair loss workup — the dermatology side of the same threshold, with finasteride and minoxidil pharmacology
• GLP-1 first 30 days survival guide — when to schedule baseline labs and what to expect early
• GLP-1 muscle loss prevention — the protein and resistance-training half of the nutrition workup

Important disclaimer. This article is educational and does not constitute medical advice. Iron supplementation interacts with thyroid hormone replacement, levodopa, tetracycline and fluoroquinolone antibiotics, and bisphosphonates; spacing of doses must be coordinated with the prescribing clinician. Patients with hemochromatosis, chronic transfusion history, or unexplained iron overload on baseline labs should not be supplemented without hematology evaluation. IV iron infusions should be administered in a setting equipped to manage hypersensitivity reactions. PMIDs were verified live against the PubMed E-utilities API on 2026-05-29.

Last verified: 2026-05-29. Next review: every 12 months, or sooner if a prospective trial of iron status changes on semaglutide or tirzepatide is published.